Sanara MedTech Inc. and InfuSystem Holdings, Inc. Announce Exclusive United States Distribution Agreement with, and Minority Investment in, ChemoMouthpiece, LLC

Core Viewpoint - Sanara MedTech Inc. has entered into an exclusive distribution agreement and minority investment in ChemoMouthpiece, LLC, aiming to enhance treatment options for oncology patients suffering from oral mucositis [1][2][3] Company Overview - Sanara MedTech Inc. focuses on developing medical technologies to improve clinical outcomes and reduce healthcare costs in surgical, chronic wound, and skincare markets [7] - InfuSystem Holdings, Inc. is a healthcare service provider that facilitates outpatient care for durable medical equipment, with a focus on oncology, pain management, and wound therapy [8] Transaction Details - Sanara invested $5 million for a 6.6% ownership stake in ChemoMouthpiece, which has developed a cryotherapy device for oral mucositis [3] - SI Healthcare Technologies, a joint venture between Sanara and InfuSystem, will exclusively distribute ChemoMouthpiece's products in the U.S. [3] - The distribution will target approximately 3,000 cancer centers through InfuSystem's existing sales team [3] Product Information - The Chemo Mouthpiece® device is designed to alleviate oral mucositis, a painful condition affecting 500,000 to 1,000,000 patients annually in the U.S. [4] - The estimated market size for oral mucositis treatment exceeds $600 million [4] - The device has received FDA 510(k) clearance and is expected to improve patient quality of life while reducing costs for oncology treatment centers [2][4] Strategic Importance - The partnership aims to leverage combined strengths in technology and operations to deliver effective products to patients [5] - The introduction of the Chemo Mouthpiece® aligns with Sanara's skincare strategy, which includes products targeting radiation dermatitis [2]